American Society of Gene & Cell Therapy. VP Medical and Patient Affairs, Encoded Therapeutics, Inc. Senior Director of Technology, Gene Therapy, Repligen Corporation, Scientist II, Technical Development, Biogen, Director, Cell and Gene Therapy, Latham Biopharm Group, Chief, Division of Cellular and Molecular Therapy, University of Florida College of Medicine, FL, USA, Hamilton, Brook, Smith & Reynolds, MA, USA, Vice President Business Development and Alliances. We use cookies to ensure that we give you the best experience on our website. As the industry-leading rare gene therapy meeting, the. Chief Medical and Development Officer, Senti Bio, Daniel S Chen, MD, PhD Precision ADVANCE, a collection of interconnected services and complementary teams across Precision for Medicine, Project Farma, and Precision Value & Health are uniquely focused on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully . It has set the aims, policies, solutions, and consensus path forward for the sector over each successive 12 months, addressing the biggest bottlenecks in cell and gene therapy development. The American Society of Gene & Cell Therapy (ASGCT) is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. The ISCT Annual Meeting is designed to connect cell and gene therapy translation professionals to educate, inspire, network, and collaborate. Gene Therapy conference listings are indexed in scientific databases like Google Scholar, Semantic Scholar, Zenedo, OpenAIRE, EBSCO, BASE, WorldCAT, Sherpa/RoMEO, Compendex, Elsevier, Scopus, Thomson Reuters (Web of Science), RCSI Library, UGC Approved Journals, ACM, CAS, ACTA, CASSI, ISI, SCI, ESCI, SCIE, Springer, Wiley, Taylor Francis, and The Science Citation Index (SCI). The International Journal of Molecular and Cellular Therapeutics. Your registration provides access to the presentations across all 8 tracks, allowing you to create an agenda tailored specifically for your needs. You also receive our free newsletter. We will explore some of the principles and mechanisms that drive success and failure of this exciting treatment modality. The Sweetheart Special is a USSSA Fast Pitch event in Jesup, GA and will be held from 02/11/2023 to 02/11/2023 An error has occurred, please try again later.An error has occurred, please try again later., Sheraton Boston Hotel Hanson Wade's goal is to accelerate progress within organisations and across industries. All cancellations must be sent by email at. CAR-T Development in China: What we Need to Know, Regulatory Considerations and Impact on the Field, Core Faculty Member / Associate Professor of Biology / Associate Professor of Neuroscience and Physiology. Cancellations received between September 19 until January 21, 2023: 50% will be refunded. Youll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business. You can also make a donation by PayPal and support the Gene Therapy Net website. Boston The four major areas of cell therapy moving forward include autologous, allogeneic, point of care and in vivo CAR-T. Sales Europe 20800 Swenson Dr. President, CTO & Co-founder, CTRL Therapeutics, Jan ter Meulen, MD, PhD With our extensive marketing experience and strategy, your partnership with Advancing Gene Therapy will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. Gene Therapy Conferences in USA 2022/2023/2024 lists relevant events for national/international researchers, scientists . Dr Isabelle Rivire provides a progress report on manufacturing platforms for cell therapy including Autologous, Allogeneic, In Vivo and Point of Care. Patients with GBA1 mutations also often have an earlier disease onset and faster progression.. GBA1 mutations also cause Gaucher's disease, a rare condition marked by the buildup of fatty molecules in . Mechanisms Driving CAR-T Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. How are companies addressing those problems? Europe's Premier Conference to Optimize Your Bioprocesses 14 - 15 March 2023 CELL CULTURE AND BIOPRODUCTION ADVANCES IN RECOVERY AND PURIFICATION GENE THERAPY CMC AND ANALYTICS CELL THERAPY MANUFACTURING ANALYTICS AND CHARACTERISATION 15 - 16 March 2023 CELL LINE DEVELOPMENT INTENSIFIED AND CONTINUOUS PROCESSING GENE THERAPY MANUFACTURING Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers. With August came the green light for bluebird bios Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Director, Cell Therapy and Cell Engineering Laboratory, Memorial Sloan Kettering Cancer Center (MSKCC), IO Cell Therapy 360 Manufacturing Showcase. More US companies are shifting resources and doing early development work out of China to advance cancer treatments for patients. Over 600 attendees. New for BPI 2022, your conference pass provides on . Registration is free and allows users complete access to all sections of the site, including archived news items. The mission of the Gene Therapy Event Series is to focus on the most challenging problems facing every aspect of the industry, sourcing leading experts with innovative solutions and distilling this into market-leading conferences. Cancellations received up and including September 18, 2022: full refund less a $80 towards the administrative fee. Lead Partner. Far from the typical meet-and-greet exhibition experience, you as a sponsor or exhibitor will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. Our mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate diseasewe do that by serving as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society. This improved outlook comes amid the company's potential blockbuster drugs tracking ahead of schedule and targeted investments in Research . The Gene Therapy team focuses on the most challenging problems facing every aspect of the industry, sourcing leading experts with innovative solutions and distilling this into market-leading global conferences. International Conference on Cell and Gene Therapy July 10-11, 2023 in Paris, France DIGITAL Conference Code: 23FRPA07ICCGT001 Submit Your Paper Author Registration Listener Registration About Venue Call For Papers Important Dates Committees Registration Fees Program Conference Photos Flyer The International Research Conference Aims and Objectives VP, Development Program Lead, Cell Therapy Development, BMS, Kanya Rajangam, MD, PhD Toll Free: +1-800-233-9014. The meeting would provide an opportunity to engage with thought leaders and researchers to discuss the latest breakthrough and the future of Cancer Immunotherapeutic Research. IO Cell Therapy 360 Debate. #CIS2023 would bring together leading pharmaceutical and biotech companies, patient advocacy groups, government and regulatory authorities, and investors and solution providers. Advisors | Brooklyn Heights is a neighborhood with more than 500 Antebellum homes and buildings. Provide your contact information and your questions through the website and a distributor will reach out to you promptly. United States. We use cookies to ensure that we give you the best experience on our website. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers. Hanson Wade's goal is to accelerate progress within organisations and across industries. This presentation will focus on a platform approach to drive the discovery of novel gene functions in T-cells or other immune cells that enhance cell function to drive enhanced persistence and enhance anti-tumor activity. Special Early Bird Rate Ends in.. Day. Insights at the meeting will enable you to: T: (+1) 617 455 4188 Rosanna Ricafort, MD Co-founder & CEO, Umoja Biopharma, Charge-up at the IO360 Charging Stations, Optional Luncheon Roundtable Discussions Director, Cellular Therapy Program and Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital. What would they like to see companies bring forward as opportunities that they would be more excited to invest in? We begin with opening remarks from our IO Cell Therapy 360 lead advisors who address the issues with cell therapy that are impacting the field, what we have learned, where we need to go from here and prepare for the challenges ahead. An event vital to unlocking the full potential of your rare gene therapy program, join us to keep your finger on the pulse and set up for success in 2023. 50+ CELL, GENE & IMMUNOTHERAPY THOUGHT LEADERS INCLUDING: Christopher A. Bravery, Ph.D. Shari Kaiser, PhD Whether through world-class speakers, original content or industry-defining databases, this knowledge is delivered through a premium customer experience. Executive Director, Global Regulatory Affairs, Kite, a Gilead Company, Jordan Schecter, MD Chief Program Officer, Alliance for Cancer Gene Therapy, Shana Kelley, PhD The. Our BPI 2022 agenda includes 8 conference tracks covering novel science across all phases of bioprocessing for biologics, cell & gene therapies. Will there ever be a place for two different modalities together, such as oncolytics and CAR-Ts? They all bring tremendous potential, challenges and limitations. This roundtable will address how to practically establish translational infrastructure that can generate actionable and informative data to support clinical trials. Kentico CMS Development by Reason One | Powered by Kentico. How are we addressing the continued issue of safety management? Pre-Filled Syringes and Injectable Drug Devices Europe, Cell & Gene Therapy Conferences at PepTalk 2023, Transdermal and Microneedle Drug Delivery, Next Generation Ophthalmic Drug Delivery Summit, 2nd Annual mRNA-Based Therapeutics Summit, 2nd Allogeneic Cell Therapies Summit Europe, 3rd TGF- for Immuno-Oncology Drug Development Summit, 6th Annual Cell & Gene Therapy Innovation Summit, Retinal Vascular Disease Drug Development Summit, 11th Alzheimers & Parkinsons (Gene Therapy) Drug Development Summit, 3rd Annual Gene Therapy for Muscular Disorders Summit, GENAP Summit 2023 - Gene & Cell Therapy Aseptic Processing Technology, 6th Antigen-Specific Immune Tolerance Summit, Cell & Gene Therapy Research & Development Congress Asia, 4th Supply Chain and Logistics for Cell Therapies Summit, 12th Spring Meeting of the International Society for BioProcess Technology, 6th Annual Gene Therapy for Rare Disorders 2023 Summit, Reuters Pharma USA 2023 - Cell and Gene Therapies, International Bioprocessing and Biologics 2023 - Cell and Gene Therapies, 2nd LNP Formulation & Process Development Summit 2023 - Gene Therapy delivery, mRNA Process Development & Manufacturing Summit Europe, The Economist's Cell & Gene Therapy summit, 4th Gene Therapy Analytical Development Europe Summit, ISBioTech Nucleic Acids meeting - Production of DNA and RNA Biotherapeutics, 2nd Next Generation RNA Therapeutics Summit, American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, Global Biologics Cell and Gene Legal Summit, Annual meeting of the Netherlands Society of Gene & Cell Therapy, Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, 31th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Your conference not listed? Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies, Rachel Haurwitz, PhD If you are unable to attend the summit at any given time, we will transfer your ticket to next year. Recent Advances in Gene Therapy Technologies scheduled on June 10-11, 2025 in June 2025 in Barcelona is for the researchers, scientists, scholars, engineers, academic, scientific and university practitioners to present research activities that might want to attend events, meetings, seminars, congresses, workshops, summit, and symposiums. OriGen Biomedical has many global distributors. VP and Head, Cellular Therapy Clinical Development, BMS, Roundtable #4: CAR-T Development in China: What we Need to Know, Regulatory Considerations and Impact on the Field. Head Business Development and Partnership, Department Chairman, Department of Urology, UT MD Anderson Cancer Center,TX, USA, SVP of Global Commercial Development & TA Strategy, CSL Behring, Senior Staff Scientist, T Cell Therapeutics Research Laboratory, Vice President, Process Development Viral Vector Technologies. Philadelphia Marriott Downtown, Philadelphia, PA. View Online Program! LEARN MORE. Director, Center for Biologics Evaluation and Research (CBER), FDA, GRAND OPENING OF THE IO Cell Therapy 360 and IO360 NETWORKING CAFE, Cell Therapy Manufacturing Progress Report and Novel Manufacturing Paradigms. Senior Director, Immuno-Oncology and Cellular Therapy Translational Research, BMS, Michael Kalos, PhD Head Office The Wayne County native and member of Calvary Baptist Church was a 1966 Jesup High School graduate and received two associate's degrees, one from South Georgia College in Douglas while playing baseball and then one at John A. Gupton School of Mortuary Science in Nashville . Advertising opportunities on Gene Therapy Net include standard size banners as well as text ads. More specifically, we will focus on the overlapping concepts of hypothesis -generating and -testing translational research, to enable more complete and actionable understanding of cell therapy activity, safety, and mechanism of action and inform empiric and rational program and pipeline development. VP & Head, Cell Therapy. SW1W 0AU, Optimize AAV & LV Formulation, Define Process CQAs to Reduce Impurity Levels & Achieve Scalability, Harness CRISPR Technology to Revolutionize Agriculture, Novel Disruptive Therapeutic & Delivery Approaches to Treat Wet-AMD, DR & DME, Deliver Safer, More Effective Gene Therapies to Muscle Cells, Collectively Changing the Paradigm for Rare Disease Treatment, Practical Insights to Optimize Your Gene Therapy Comparability Approach, Deliver High Quality, Durable Therapies to Patients in Need, Develop, Validate & Implement Analytical Methods, Accelerating Europes Progress in CNS Gene Therapy, Effectively Implementing Patient-Centric Gene Therapy Development, Optimizing Viral & Non-Viral Gene Therapy Delivery, Predict & Monitor AAV Safety Signals to De-Risk Genetic Therapy Development, Revolutionize the Treatment of Inner Ear Disorders, Optimizing Clinical and Pre-Clinical Immunogenicity Assays and Strategies, Revolutionizing Genetic Therapy Development & Delivery to the Eye, Delivering the Next Wave of Gene Therapies to the CNS, Progressing Next Generation Gene Editing Therapeutics, The Comprehensive Gene Therapy Analytical Event, Expert-Driven, Life Science Market Intelligence, Gain Confidence in Your Gene Therapy Drug Development Decisions. Gene Therapy Conferences 2023 10 - 12 January 2023 Pre-Filled Syringes and Injectable Drug Devices Europe London, UK 16 - 20 January 2023 Cell & Gene Therapy Conferences at PepTalk 2023 San Diego, CA 23 - 24 January 2023 Transdermal and Microneedle Drug Delivery London, UK 24 - 26 January 2023 Next Generation Ophthalmic Drug Delivery Summit Core Faculty Member / Associate Professor of Biology / Associate Professor of Neuroscience and Physiology, New York Genome Center / New York University / NYU Grossman School of Medicine. Phil Tai, PhD, shareshis top 10 tips. Visit our contact page for a quick response. Senior Director, ICT Development, Arsenal Bio, Oliver Nussbaumer, MD, PhD DQUAD 2023 is the industry lead summit, dedicated to bringing together pharma and biotech pioneers at the forefront of drug discovery, delivery and development, discussing the latest scientific breakthroughs, exploring innovative technologies and approaches to overcome drug discovery and development challenges, and future opportunities for novel therapeutic discovery. Terms and Conditions, New York Marriott at the Brooklyn Bridge, Brooklyn, NY, Investor Perspective on the State of the Current Market and Impact on the IO Cell Therapy Field, Addressing the Translational Research Paradigm And Generating the Right Information From your Translational Studies to Have Greater Impact, Senior Director, Immuno-Oncology and Cellular Therapy Translational Research, Cell Therapy Combinations: Key Questions, Challenges and Progress. Tel: +1-512-474-7278 We would love for you to be one of them. We will: Bring together multinational regulatory bodies, including the, Enhance regulatory understanding to better inform clinical and manufacturing programmes, Navigate new regulatory designations and accelerated pathways, Designing and implementing safe and effective clinical trials, understanding the process behind defining primary endpoints, The operational intricacies behind rare gene therapy trials, Gearing up for registrational clinical trials, Leveraging innovative platforms, using the latest advances in technology to improve manufacturing efficiency, Navigating key bottlenecks in rare disease CMC to scale up effectively, Demonstrating comparability to regulatory bodies in light of process changes, Define the value of your rare gene therapy, Effectively set up your cross-functional team to be prepared for launch, Ensure rare disease patients have access to gene therapies, and the practicalities surrounding early access. 70 3rd Ave, Waltham, MA 02451, United States. CSO, Mnemo Therapeutics, TRACK C: HARNESSING THE FULL POTENTIAL OF TUMOR REACTIVE LYMPHOCYTES, Barbara Lavery EVENT CALENDAR Up Next: Advanced Therapies Week 2023, Miami, Florida Advanced Therapies Week is the destination for developers, investors and solution providers whose goal is to bring cell and gene therapies to patients. About Us | Boston From promise to reality: Delivering transformative therapies to patients. The 2020 Wayne County High School graduate and four-year letterman in soccer had plans to pursue a criminal justice degree. There are a variety of ways you can support the 26thAnnual Meeting. Managing Director, Next Pillar Consulting, Ramy Ibrahim, MD This session will focus on key learnings cleaned from the full clinical development pathway- from first-in-human through launch to commercialization for each of the to-date approved autologous cell therapy products. Get in touch and we will get back to you. Go West in 2023! #VSBOSTON provides an iconic platform where science, and business converge. Registration is free and allows users complete access to all sections of the site, including archived news items. FDA Updates on Cell Therapy Email: Sales / General Whats Unique to Cell Therapy Clinical Development That Can Help Solve Challenges the Industry May Face? Present your research and cases to your colleagues and peers to get feedback, new ideas, and recognition, and make a name for yourself in the field. . Berlin, January 10, 2023 - On the occasion of the 41 st J.P. Morgan Healthcare conference in San Francisco, Bayer AG announced it is raising its combined peak sales forecast for key growth drivers in its pharma portfolio to over twelve billion euros. . On June 26, please join us at our Rare Disease Therapeutic Alliance 2023, which will feature 1on1 meetings with the select group of specialty pharma and biotech companies focused on developing therapies for some of the rare and orphan diseases. How do we get the t-cell redirecting field, it could be CART or bispecifics, working effectively with adaptive immune modulators? This rapid-style session features updates from companies specializing in CAR-T modifications on progress, challenges and next steps. VP, R&D, Director, Defence Therapeutics Inc, Laura Johnson, PhD Home | Minute. (Andrii Yalanskyi/Shutterstock) PitchBook analyst Aaron Degagne reports from JP Morgan's healthcare conference in San Francisco with some gene therapy news: Startup ReCode Therapeutics has struck new partnerships with Bayer's AskBio and the Cystic Fibrosis Foundation. For additional queries regarding accommodation, please contact: In addition, the summit covers emerging and related fields including Gene Editing & CRISPR, Cell Therapies, Gene Therapy for Cancer, Immunotherapy, Rare diseases, Blood Disorders, Neurological Disorders, Toxicology Studies, advances in manufacturing, regulatory and medical affairs, Commercialization Strategies, Business Models and Market Access.